Defence Therapeutics Inc. (DTC.CN)
| Previous Close | 3.6700 |
| Open | 3.6000 |
| Bid | 3.5300 x N/A |
| Ask | 3.6900 x N/A |
| Day's Range | 3.6000 - 3.6000 |
| 52 Week Range | 1.4500 - 4.8500 |
| Volume | |
| Avg. Volume | 36,075 |
| Market Cap | 136.257M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1430 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it is currently conducting a final pre-clinical study aimed at validating the efficacy of AccuTOXTM combined to immune-checkpoint inhibitors akin to the clinical design to be used on p
- Newsfile
Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that over the course of the last 6 months the Company has received over $5 million in gross proceeds from the exercise of warrants, pursuant an early warrant exercise program (the "Early Warrant Exercise Program").To
- Newsfile
Defence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is pleased to announce that it has signed a Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation of radio-immunoconjugates for radio-immunotherapy using Defence's intracellular targeting technology. The no
